ModifiedUnitedHealthcarePolicy CS107TN.AE

Rhinoplasty and Other Nasal Procedures (for Tennessee Only)

Medical policy governing coverage criteria for rhinoplasty and other nasal procedures for Tennessee Medicaid and CoverKids members, including indications, documentation, and coding guidance for reconstructive versus cosmetic procedures.

Policy Summary

PayerUnitedHealthcare

PolicyRhinoplasty and Other Nasal Procedures (for Tennessee Only)

Policy CodePolicy CS107TN.AE

Change TypeDocumentation and operational clarificationsdefinitional updates

Effective DateMay 1, 2026

Next Review Date

Key ActionEnsure medical records document history, exam, diagnostic test results, photos, baseline symptom scores, prior conservative therapy, and a clear surgical plan to support medical necessity.

SourceLink

POLICY UPDATE CHANGES

Added language clarifying that benefit coverage is determined by federal, state, or contractual requirements and that medical records documentation may be required to assess whether the member meets clinical criteria for coverage.

Specified that the patient's medical record must contain documentation that fully supports medical necessity and listed examples of required documentation elements.

Updated definition of 'External Nasal Valve.'

Updated Clinical Evidence and References sections to reflect current information.

Archived previous policy version CS107TN.AD.

multipleCovered topics

6+Criteria groups

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Unproven procedures listed

53Systematic review studies

137Randomized participants (Latera RCT)

multipleReference citations

Coverage Criteria and Evidence Considerations

Nasal valve procedures/repair of nasal vestibular stenosis or alar collapse (Reconstructive / Medically Necessary)

Covered when ALL of the following are met

Main criteria set: Prolonged, persistent, obstructed nasal breathing due to internal and/or External Nasal Valve compromise; other causes of nasal obstruction have been adequately treated with maximal therapy and obstruction persists; nasal septal deviation and turbinate hypertrophy are either absent, previously surgically treated, or scheduled to be treated at the same time as the nasal valve procedure; documented visible collapse of alar (lower lateral) cartilage and/or lateral nasal wall with deep inspiration; documented subjective and audible improvement in nasal airflow during modified Cottle maneuver; photos clearly document dynamic collapse or anatomical deformity as a main cause of mechanical nasal airway obstruction and are consistent with the clinical exam; and the surgeon has provided a clear description of whether the compromise is static or dynamic, whether internal and/or External Nasal Valve are involved, and a plainly stated surgical plan including need for cartilage graftall items required

All listed criteria must be met

Rhinophyma excision (Reconstructive / Medically Necessary)

Covered when ALL of the following are met

Rhinophyma criteria: Either prolonged, persistent, obstructed nasal breathing due to rhinophyma OR chronic infection or bleeding from rhinophyma unresponsive to medical management; photos clearly document rhinophyma as the primary cause of mechanical nasal airway obstruction or chronic infection and match the clinical examination; and the proposed procedure is designed to correct the anatomical obstruction or to address the chronic infectionall items required

All listed criteria must be met

Rhinoplasty for congenital anomalies (Reconstructive / Medically Necessary)

Covered when the following is present

Congenital anomaly indication: Rhinoplasty performed for a nasal deformity associated with congenital craniofacial anomalies (e.g., Pierre Robin, Apert, Fraser, Binder, Goldenhar, nasal dermoids, Tessier nasal cleft) or associated with cleft lip or cleft palateall items required

Single criterion required

Rhinoplasty - primary (Reconstructive / Medically Necessary)

Covered when ALL of the following are met

Primary rhinoplasty criteria: Indication is prolonged, persistent, obstructed nasal breathing due to nasal bone and septal deviation as primary causes; or nasal fracture with displacement causing obstruction; or residual large cutaneous defect after malignancy/trauma; the nasal airway obstruction cannot be corrected by septoplasty alone (documented); photos document nasal bone/septal deviation as the primary cause and match exam; the procedure is designed to centralize the bony pyramid and straighten the septum to relieve obstruction; obstruction causes significant symptoms (e.g., chronic rhinosinusitis, difficulty breathing); and obstructive symptoms persist despite conservative management for 4 weeks or greater (where appropriate including nasal steroids or immunotherapy)all items required

All listed criteria must be met

Rhinoplasty - revision (Reconstructive when specific)

Covered when ALL of the following are met

Revision rhinoplasty criteria: Required to treat a complication or residual deformity from primary surgery that was performed to address a functional impairment when documented functional impairment persists due to the complication/deformity; photos clearly document the secondary deformity/complication as the primary cause of mechanical nasal airway obstruction and match exam; the proposed procedure is designed to correct the deformity or treat the complication to relieve obstruction; obstruction causes significant symptoms (e.g., chronic rhinosinusitis, difficulty breathing); and obstructive symptoms persist despite conservative management for 4 weeks or greater (where appropriate including nasal steroids or immunotherapy)all items required

All listed criteria must be met

Rhinoplasty - tip (Reconstructive when specific)

Covered when ALL of the following are met

Tip rhinoplasty criteria: Prolonged, persistent, obstructed nasal breathing due to tip drop as the primary cause of mechanical nasal airway obstruction; photos clearly document tip drop as the primary cause and match exam (e.g., acute columellar–labial angle); the procedure is designed to lift the nasal tip to relieve obstruction; obstruction causes significant symptoms (e.g., chronic rhinosinusitis, difficulty breathing); and obstructive symptoms persist despite conservative management for 4 weeks or greater (where appropriate including nasal steroids or immunotherapy)all items required

All listed criteria must be met

Nasal polypectomy

Covered when consistent with referenced InterQual criteria

Nasal polypectomy: Medical necessity determined per InterQual CP: Procedures, Polypectomy, Nasal; providers should refer to InterQual clinical criteria for specific coverage determinationrefer to external criteria

Policy delegates specific clinical criteria to InterQual

General coverage rationale

Coverage considerations and evidence summary

Evidence and patient selection: Surgical repair of the nasal valve can improve nasal obstruction for appropriately selected patients; proper targeted evaluation to identify the specific cause/site of internal nasal valve collapse is required prior to selecting a surgical approach; treatment should be directed at the specific anatomic site and individualized to the patient's problem

Supported by systematic reviews and AAO-HNS position statement

Technique options: Treatment options include cartilage grafting, open repair, suture suspension, implants, or radiofrequency targeting nasal valve stabilization

AAO-HNS lists these approaches; choice should be individualized

Implant evidence: Absorbable lateral wall implants (e.g., Latera) show short-term improvements in patient‑reported nasal obstruction measures but overall evidence quality is low with limited long-term comparative data versus rhinoplasty; randomized sham‑controlled trials with longer follow-up are needed

ECRI and Hayes reviews note low quality and need for longer-term RCTs

Absorbable nasal cartilage support implants — evidence synthesis

Evidence summary and coverage considerations for absorbable nasal implants (Latera):

Evidence summary: Randomized and nonrandomized studies report improvements in disease‑specific QOL and NAO measures with absorbable lateral wall implants up to 12–24 months in some cohorts; multicenter RCTs have shown superiority to sham at short‑term follow-up, but overall study quality is limited by small samples, heterogeneous concomitant procedures, subjective outcomes, risk of bias, and inadequate long‑term comparative data versus rhinoplasty

Well‑designed, longer‑term randomized trials comparing implants to surgical alternatives are lacking

Nasal septal swell body reduction — evidence synthesis

Evidence summary and coverage considerations for nasal septal swell body (SSB/NSB) reduction:

Evidence summary: Small studies and systematic reviews report that septal swell body reduction using RFA, coblation, microdebridement, or TCRF can improve nasal obstruction scores up to 12–24 months; pooled analyses show significant improvements with low adverse event rates but studies are limited by small sizes, heterogeneity, short follow‑up, and lack of standardized outcomes or control groups

Additional robust randomized trials with longer follow‑up are needed

PNN/SPG ablation — Candidate selection

Covered when ALL of the following are met (based on populations studied):

Eligibility: Adult with chronic rhinitis of >= 6 months duration refractory to medical managementduration >=6 months; inadequate response to >=4 weeks of intranasal steroids/other nasal medications

Reflects inclusion criteria used in multiple prospective studies and RCTs

Symptom severity: Baseline validated symptom score meeting trial thresholds (e.g., rTNSS >=6 or equivalent TNSS) with required subscores for rhinorrhea/congestion when specified by trialrTNSS >=6 and subscores as specified in pivotal trials

Matches entry criteria used in pivotal randomized and prospective studies

Trial of medical therapy documented: Documented trial and inadequate response to topical intranasal corticosteroids, antihistamines, and/or anticholinergics prior to procedure

Septal body (NST/SB) reduction — Candidate selection

Covered with criteria when ALL of the following are met (based on available studies):

Anatomic contributor: Documented septal body hypertrophy or abnormally thickened nasal septal swell body contributing to nasal obstruction (confirmed by imaging or endoscopy)documented NSB enlargement (e.g., mean maximal NSB width ~16 mm reported in cohorts)

Studies selected patients with demonstrable septal body enlargement

Prior medical and anatomic therapy: Inadequate symptom relief after appropriate medical therapy and after prior turbinate or septal interventions when applicablehistory of failed prior SPL and turbinate reduction in some studies

Some studies included patients with prior surgical failure

Intervention types with supporting evidence: Coblation, RFA (including TCRF), or microdebrider‑assisted submucosal resection have small studies showing short‑term symptom improvement

Limitations and situations lacking sufficient evidence

Considered not established when ANY of the following apply:

Insufficient long-term evidence: Procedures lacking adequate randomized controlled data or long‑term follow‑up (e.g., many cryoablation studies, some NST techniques) to demonstrate durable benefitlack of high‑quality long‑term RCT data

Multiple reviews call for larger, independent RCTs

Heterogeneous or industry‑sponsored evidence: Evidence primarily from single‑arm studies, small cohorts, or industry‑sponsored trials with potential bias limiting generalizabilityindustry sponsorship or high heterogeneity noted

Limits strength of conclusions

Initial coverage criteria (example constructs)

Covered when ALL of the following are met (examples derived from trial eligibility and guideline position statements):

Baseline symptom severity: Validated symptom score meeting trial thresholds (examples: rTNSS >=4–6 for chronic rhinitis trials; NOSE >=60 for nasal valve trials)rTNSS >=4–6; NOSE >=60

Trials used varying thresholds; prior authorization should reference specific numeric criteria used locally

Failure of conservative therapy: Documented inadequate response to appropriate medical therapy (e.g., at least 4 weeks of intranasal steroids for chronic rhinitis or other nasal medications) prior to consideration of device‑based or surgical procedures>=4 weeks intranasal steroid or other appropriate medical therapy

Several studies required prior medical therapy before enrollment

Anatomic/clinical target confirmation:

Procedures that are not explicitly listed in the policy’s reconstructive indications for nasal valve repair, nasal vestibular stenosis repair, or alar collapse are not considered reconstructive and not medically necessary. The policy requires that all specified clinical criteria for the listed procedures be met (e.g., documented persistent obstruction attributable to the valve, prior treatment of other causes, visible dynamic or static collapse on exam, modified Cottle maneuver improvement, photographic correlation, and a clear surgical plan including whether a cartilage graft is needed). If the documented case does not meet every required element for the indicated procedure, the intervention does not meet the policy’s reconstructive coverage criteria.

The policy identifies several device- and procedure-based interventions as unproven and not medically necessary because available evidence is insufficient to establish safety or durable effectiveness. These include absorbable polylactic acid nasal cartilage support implants (e.g., Latera), nasal septal swell body (SSB/NSB) reduction, and posterior nasal nerve or sphenopalatine ganglion (PNN/SPG) ablation methods such as cryoablation or radiofrequency. The listing reflects the policy’s conclusion that current studies do not provide adequate high‑quality, long‑term comparative data to support routine coverage of these interventions for the treatment of nasal airway obstruction or chronic rhinitis.

Interventions for nasal valve collapse must be preceded by an appropriate targeted clinical evaluation to identify the specific anatomic site(s) contributing to obstruction. Systematic reviews and guideline statements emphasize that failure to determine whether internal valve, external valve, lateral wall, septal, or turbinate pathology is the predominant contributor can lead to inappropriate procedure selection and suboptimal outcomes. Procedures performed without documentation of a focused evaluation and tailored treatment plan may therefore be considered unsupported by the evidence and subject to denial.

Overall evidence for many newer device‑based nasal procedures is limited by small sample sizes, short follow‑up, heterogeneous concomitant procedures, subjective outcome measures, and risk of bias. The policy notes a paucity of robust randomized controlled trials and long‑term comparative data versus established surgical techniques; these evidence limitations reduce confidence in conclusions about comparative effectiveness and durability and may affect coverage decisions.

Procedures that are performed as a first‑line therapy without documentation of an adequate trial of appropriate medical management (for example, at least 4 weeks of intranasal steroids or other indicated nasal medications where applicable, and often longer for chronic rhinitis) are not aligned with populations studied in the evidence base and may be considered not medically necessary. The policy expects documentation that conservative measures were attempted and were inadequate before device‑based or surgical interventions are undertaken.

There is an absence of adequate evidence comparing devices and procedural alternatives (for example, absorbable implants versus autologous cartilage grafting or functional rhinoplasty) and a lack of long‑term durability data beyond a few years for many technologies. Because comparative effectiveness and durability remain uncertain, the policy highlights concerns about substituting minimally invasive device approaches for established reconstructive procedures without justification and long‑term outcome data.

The policy states that FDA approval or clearance alone is not a basis for coverage. Regulatory status is provided for informational purposes, but coverage determinations are based on the totality of clinical evidence and whether the procedure meets the policy’s medical necessity criteria.

The policy explicitly lists specific procedures considered unproven and not medically necessary because of insufficient evidence of safety and/or efficacy. These procedures include absorbable polylactic acid nasal cartilage support implants (e.g., Latera), nasal septal swell body reduction, posterior nasal nerve/sphenopalatine ganglion ablation (any method such as radiofrequency or cryoablation, e.g., RhinAer, ClariFix), and radiofrequency treatment of nasal valves (e.g., VivAer). The listing indicates these interventions lack adequate high‑quality data to support routine reconstructive coverage.

Use of absorbable nasal implants as an alternative to definitive rhinoplasty or autologous grafting should be justified in the medical record; evidence reviews note uncertainty about comparative long‑term effectiveness versus rhinoplasty. Without documentation explaining why a permanent reconstructive approach is inappropriate or why an implant is preferred for the individual patient, substitution of absorbable implants for rhinoplasty may be considered unsupported.

Procedures that rely solely on placement of absorbable nasal implants or isolated SSB/NSB reduction—without clear documentation that the implant or septal swell body is the anatomic contributor to the patient’s obstruction and without validated baseline symptom measures—are unlikely to match populations studied and may be considered not medically necessary. The policy requires objective/photographic documentation and concordant clinical exam findings showing the contributor lesion before coverage is supported.

Per evidence reviews summarized in the policy, the ClariFix cryoablation device currently has minimal or unclear support in the literature. Updated Hayes and other evidence assessments report limited-quality studies and mixed results, so indiscriminate use of ClariFix without alignment to trial populations or stronger independent evidence is not supported by the policy.

Claims for procedures lacking required documentation of symptom severity (for example, validated baseline NOSE or rTNSS scores), lacking evidence of prior appropriate medical management, or performed for indications not supported by the evidence (such as purely cosmetic reshaping without functional impairment) may not meet medical necessity criteria. The policy specifies that absence of these documented elements can lead to noncoverage.

Applicable Codes and Coding Guidance

Applicable CPT/HCPCS Codesmixed

30117	Excision or destruction (e.g., laser), of intranasal lesion; internal approach.
30120	Excision or surgical planing of skin of nose for rhinophyma.
30400	Rhinoplasty, primary; lateral and alar cartilages and/or elevation of nasal tip.
30410	Rhinoplasty, primary; complete, external parts including bony pyramid, lateral and alar cartilages, and/or elevation of nasal tip.
30420	Rhinoplasty, primary; including major septal repair.
30430	Rhinoplasty, secondary; minor revision (small amount of nasal tip work).
30435	Rhinoplasty, secondary; intermediate revision (bony work with osteotomies).
30450	Rhinoplasty, secondary; major revision (nasal tip work and osteotomies).
30460	Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip only.
30462	Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip, septum, osteotomies.

1–10 of 18

1/2

Procedures discussed (no codes listed)mixed

not specified

Procedural techniques described include radiofrequency ablation (RFA), coblation, cryoablation, microdebrider-assisted submucosal resection, temperature-controlled radiofrequency (TCRF) neurolysis, and septal body volume reduction; no explicit CPT/HCPCS codes listed in these sections.

FDA product codes / device classifications mentionedmixed

LRC	Instrument; ear, nose, and throat (ENT); manual surgical (FDA product code; includes devices used for rhinoplasty and sinus surgery).
LYA	Intranasal septal splint devices (FDA product code; Class I devices category).

FDA 510(k) clearances referencedmixed

K200300

VivAer Stylus 510(k) clearance ID (VivAer nasal airway remodeling stylus).

FDA 510(k) clearances referencedmixed

K161191

Latera Absorbable Nasal Implant 510(k) clearance ID.

FDA product codes referencedmixed

LRC	Product code for instruments; ear, nose, and throat (ENT); manual surgical.
LYA	Product code for intranasal septal splint devices.

Device 510(k) identifiersmixed

K200300

VivAer Stylus 510(k) clearance (VivAer nasal airway remodeling stylus).

Device 510(k) identifiersmixed

K161191

Latera Absorbable Nasal Implant 510(k) clearance.

Device 510(k) identifiersmixed

K190356	ClariFix Device 510(k) clearance.
K221907	RhinAer Stylus 510(k) clearance.

Medical management trial — recommended duration before surgery

Recommended duration (rhinoplasty indications)At least 4 weeks of conservative medical management is expected prior to surgery for many rhinoplasty indications.

Definition for prolonged obstructionFailure to respond to 6 weeks of medical management (e.g., nasal steroids, antihistamines, decongestants) defines prolonged, persistent nasal airway obstruction.

Range noted in policy summaryPolicy references a trial period range of >=4–6 weeks depending on the specific indication and coverage criteria.

rTNSS eligibility threshold used in trials

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Implant interventions — expect review

Implant interventions (for example, absorbable nasal cartilage support implants such as Latera) and other device-based treatments are subject to focused review due to limited-quality evidence and inadequate long-term outcomes data. Providers should expect prepayment or pre-service scrutiny of device placement, rationale for device selection, and supporting clinical documentation demonstrating that implant use is indicated for the patient’s specific anatomy and symptoms.

Absorbable implant procedures may trigger additional clinical review due to low-quality evidence and limited long-term follow-up.
When implants are used in combination with other nasal procedures, documentation must clearly justify the incremental benefit of the implant versus alternative reconstructive techniques (e.g., autologous cartilage grafting).

Prior Authorization

Prior authorization recommended for PNN/SPG ablation

Posterior nasal nerve (PNN) / sphenopalatine ganglion (SPG) ablation procedures should be considered for prior authorization review. Requests should include documentation that the patient meets trial eligibility consistent with clinical studies: chronic rhinitis for ≥6 months, baseline validated symptom scores meeting study thresholds (for example 24-hour rTNSS ≥6 with required subscores), and failure of prior medical management.

Key Definitions and Background

Mechanical nasal airway obstruction refers to difficulty breathing through the nose due to bony or cartilaginous deformity. The External Nasal Valve comprises the caudal edge of the lateral crus of the lower lateral cartilage, soft tissue alae, membranous septum, and the nostril sill; dysfunction of these structures can produce symptomatic nasal airway obstruction requiring reconstructive intervention when conservative measures fail.

Mechanical Nasal Airway Obstruction — definition

Mechanical Nasal Airway Obstruction — definitionTrouble breathing through the nose (not snoring) due to a bony or cartilaginous deformity.

Typical causesIncludes deformities of nasal bones, septum, lateral wall and cartilaginous structures that impede airflow.

Clinical relevanceUsed to define patient populations eligible for reconstructive nasal procedures addressing functional obstruction.

External Nasal Valve — definition

Policy Revision History

2026-05-01RevisionLatest

Added operational clarifications to medical records documentation and specified that benefit coverage is subject to federal, state, contractual requirements and applicable laws; enumerated required documentation elements (history, exam, diagnostic results) and availability upon request.

Policy Summary

PayerUnitedHealthcare

PolicyRhinoplasty and Other Nasal Procedures (for Tennessee Only)

Policy CodePolicy CS107TN.AE

Change TypeDocumentation and operational clarificationsdefinitional updates

Effective DateMay 1, 2026

Next Review Date

Key ActionEnsure medical records document history, exam, diagnostic test results, photos, baseline symptom scores, prior conservative therapy, and a clear surgical plan to support medical necessity.

SourceLink

On This Page

>=4 weeks of adequate medical therapy

Reflects eligibility criteria in multiple single‑arm and controlled studies

studies typically follow 3–12 months

Evidence limited by small size and short follow‑up

Clinical assessment confirms the targeted anatomic contributor (e.g., PNN‑related rhinitis or internal/external nasal valve collapse) is the primary contributor to symptoms

clinical diagnosis by ENT with documentation

Studies specified target anatomic region for device application

Informed consent and discussion of evidence: Patient counseled on limited long‑term comparative data, potential need for additional procedures, and device‑specific risks with documentation of informed consentdocumented consent

Professional society statements endorse use in select medically refractory cases but note evidence gaps

Typical trial eligibility thresholdBaseline rTNSS (reflective or total) commonly required to be ≥ 6 in pivotal trials (24-hour or 12-hour rTNSS depending on study).

Alternate minimums seen in trialsSome studies used lower total rTNSS thresholds (e.g., ≥4) for enrollment or secondary analyses.

Use in prior-authorization decisionsPrior authorization recommendations reference rTNSS ≥6 (or equivalent TNSS) to align with trial entry criteria for neuroablative procedures.

rTNSS subscore thresholds

Rhinorrhea subscore requirementSome trials required a rhinorrhea subscore minimum of 2–3 for enrollment.

Congestion subscore requirementSome trials required a congestion subscore minimum of 1–3 depending on the study eligibility criteria.

Other subscore rangesTrials sometimes specified subscores for itching, sneezing, or postnasal drip with ranges 0–3 when applied.

rTNSS baseline threshold

Example total rTNSS thresholdsTrials used total rTNSS enrollment thresholds ranging from ≥4 up to ≥6, with specific subscore minimums in some protocols.

Trial-specific subscore examplesExample entry criteria include total rTNSS ≥4 with rhinorrhea ≥2 and congestion ≥1 in some randomized trials.

Documentation recommendationPolicy advises documenting baseline rTNSS/TNSS consistent with the numeric criteria used in the specific evidence base for the procedure.

NOSE baseline threshold

NOSE Scale thresholds in nasal valve/TCRF studiesMany nasal valve studies enrolled patients with NOSE Scale scores ≥60; pivotal cohorts often had baseline NOSE near 76–80.

Pivotal study examplesSilvers et al. RCT baseline mean NOSE ~76–79; Yao et al. cohort baseline mean NOSE ~80.3 in participants completing 2-year follow-up.

Prior-authorization guidancePolicy suggests requiring baseline NOSE ≥60 to align with trial entry criteria for nasal valve remodeling procedures in authorization reviews.

Document baseline rTNSS and subscores consistent with published RCT criteria (e.g., total rTNSS ≥6 and specified rhinorrhea/congestion subscores where applicable).
Provide evidence of inadequate response to at least 4 weeks of appropriate intranasal corticosteroids and other medical therapies prior to neuroablative procedures.
Include procedural device name/technique (e.g., TCRF, cryoablation), treatment sites, and planned follow-up assessment schedule.

Denial Risk

Procedures will be considered not reconstructive if criteria are not met

Procedures will be considered not reconstructive and not medically necessary unless ALL documented clinical criteria specific to each procedure are met (e.g., demonstrable mechanical nasal airway obstruction, photographic documentation, trial of conservative management, and clear surgical plan). Claims lacking required criteria may be denied as cosmetic or nonreconstructive.

Ensure documentation addresses all listed coverage criteria for nasal valve repair, rhinoplasty variants, and vestibular repair.
If nasal septal deviation or turbinate hypertrophy are present, document prior surgical treatment or contemporaneous surgical plan addressing these contributors.

Denial Risk

Procedures listed as unproven (not medically necessary)

The following procedures are considered unproven and are not medically necessary due to insufficient evidence of safety and/or efficacy: absorbable polylactic acid nasal cartilage support implants (e.g., Latera), nasal septal swell body reduction, posterior nasal nerve or sphenopalatine ganglion ablation (any method) for chronic rhinitis, and radiofrequency treatment of nasal valves (e.g., VivAer ARC Stylus) when used outside established indications. Requests for these procedures are subject to denial.

Absorbable polylactic acid nasal implants (Latera) — categorized as unproven in this policy.
PNN/SPG ablation (radiofrequency or cryoablation) — considered unproven for specified indications in this policy unless criteria and evidence align with accepted study populations.
Radiofrequency remodeling devices for nasal valves (e.g., VivAer) — considered unproven for NAO in this policy context.

Documentation Required

Need for targeted evaluation

Targeted diagnostic evaluation to identify the precise anatomical or dynamic cause of nasal obstruction is required. Interventions without documentation demonstrating site-specific evaluation (e.g., internal vs external nasal valve, static vs dynamic collapse) may result in coverage review or denial.

Document focused clinical examination, modified Cottle maneuver results, and whether collapse is static or dynamic.
Include photographic or video documentation clearly showing the anatomic or dynamic contributor to obstruction.
Describe how the planned procedure specifically addresses the identified anatomic site.

Denial Risk

Evidence limitations may trigger coverage review

Evidence limitations — including low-quality studies, lack of long-term follow-up, absence of robust comparative trials, or heterogeneity of adjunctive procedures — may trigger additional coverage review and justification requests for certain device-based or novel interventions.

Be prepared to provide pertinent literature or rationale when requesting coverage for implants or newer device therapies.
Long-term outcome data and comparative evidence may be requested to support medical necessity for device-based interventions.

Denial Risk

Failure of medical management may lead to noncoverage

Failure of prior medical management is a common denial risk. Procedures performed without documentation of an adequate trial of conservative therapy (for example, at least 4 weeks of appropriate nasal medications or, where indicated, ≥6 weeks of medical management for prolonged obstruction) may be considered noncovered.

Document dates, duration, and specific medications tried (e.g., intranasal corticosteroids, antihistamines, anticholinergics) and the clinical response.
If a shorter trial is clinically justified, include rationale and supporting clinical notes.

Denial Risk

Lack of adequate medical record documentation — denial risk

Medical record documentation must fully support medical necessity and be available upon request. Lack of adequate, legible documentation (history, physical exam, diagnostic test results, photos/videos, and clearly stated surgical plan) may result in denial of coverage.

Include relevant history, physical examination findings, objective test results, validated baseline symptom scores (NOSE, rTNSS), and clear photographic/video documentation.
Maintain records that demonstrate chronicity, prior treatments, and the specific anatomic rationale for the proposed intervention.

Documentation Required

Medical record must document relevant history, exam, diagnostics, and photos

The patient's medical record must document the relevant history, targeted physical examination, diagnostic test results, and clear photographic or video evidence of the anatomical or dynamic contributors to nasal obstruction. Documentation should also specify whether the valve compromise is internal, external, or both, and present a plainly stated surgical plan including justification for grafts or implants.

Document whether nasal valve compromise is static or dynamic and whether internal and/or external valves are involved.
Include modified Cottle maneuver findings and expected objective/audible improvement.
Photographs or intraoperative images must clearly correlate with the clinical exam and proposed procedure.

Documentation Required

Clinical evaluation documentation — identify contributors to nasal obstruction

Clinical evaluation documentation must demonstrate identification of nasal valve dysfunction and assessment of other potential causes of nasal obstruction. Records should show that alternative contributors (e.g., rhinosinusitis, allergic rhinitis, turbinate hypertrophy) have been evaluated and appropriately managed or planned for concurrent treatment.

Provide evidence that other causes of nasal obstruction were considered and treated when applicable.
If septal deviation or turbinate hypertrophy contribute, document prior treatment or planned concurrent surgical approach.

Documentation Required

Required clinical documentation for coverage review

Required clinical documentation for procedural requests includes diagnosis of nasal valve collapse or septal swell body hypertrophy, baseline validated symptom scores (e.g., NOSE for nasal obstruction, rTNSS for chronic rhinitis), photos or videos documenting the anatomic/dynamic problem, and documentation of prior conservative management (typically ≥4 weeks, or ≥6 weeks where specified).

Attach baseline NOSE or rTNSS scores and date measured.
Document duration of symptoms (chronicity) and details of prior medical therapy trials, including medications and duration.
Provide operative plan specifying technique, graft/implant rationale, and targeted anatomic site(s).

Step Therapy

Conservative management expected prior to procedure

Conservative management (for example, intranasal corticosteroids, antihistamines, decongestants, anticholinergics, or immunotherapy where appropriate) should be attempted for at least 4–6 weeks prior to considering surgical or device-based interventions unless there is a clear, documented anatomic indication or prior therapies are contraindicated or previously tried.

Document specific medications, doses, dates, and response.
If step therapy is being bypassed due to clinical urgency or specific guideline recommendations (for example, AAO-HNS statements regarding drug-eluting implants), provide supporting rationale and documentation.

Documentation Required

Procedure selection justification

When selecting between procedural options (e.g., autologous cartilage grafting versus implant-based approaches), the choice should be justified in the medical record with reference to comparative effectiveness, patient anatomy, prior treatments, and surgeon rationale.

Document why a chosen technique is preferred for the individual patient, including why alternatives are not appropriate or were previously unsuccessful.
Include evidence of informed consent discussing the comparative benefits, risks, and uncertainties associated with implantable devices versus grafting.

External Nasal Valve — definitionIncludes the caudal edge of the lateral crus of the lower lateral cartilage, soft tissue alae, membranous septum, and sill of the nostril; it is the entrance to the nose.

Role in obstructionExternal nasal valve structures can contribute to nasal airway obstruction and may be targeted with surgical repair or stabilization techniques.

Guideline contextAAO-HNS recognizes nasal valve repair as a distinct procedure; approaches may include grafting, suture suspension, implants, or radiofrequency stabilization.

Prolonged, Persistent Nasal Airway Obstruction — definition (6 weeks medical management)

Prolonged, Persistent Nasal Airway Obstruction — definitionTrouble breathing through the nose that has not responded to 6 weeks of medical management such as nasal steroids, antihistamines, and decongestants; excludes drug-induced rhinitis.

Implication for coverageThis 6-week threshold is used to define prolonged obstruction for coverage criteria and differentiates cases requiring surgical evaluation.

Related documentationProviders should document prior medical therapy and chronicity consistent with this definition when seeking coverage for reconstructive procedures.

Rhinoplasty — definition and scope

Rhinoplasty — definitionA surgical procedure that alters the shape or appearance of the nose while preserving or enhancing the nasal airway; may include adjunctive procedures on the septum, turbinates, or nasal valve when they impact nasal shape or function.

Scope — functional vs cosmeticPrimary reason for rhinoplasty can be aesthetic, functional, or both; adjunctive procedures without impact on nasal shape are not considered rhinoplasty per AAO-HNS guidance.

Reconstructive contextRhinoplasty performed to correct congenital anomalies, posttraumatic deformity, or functional airway impairment may be considered reconstructive and medically necessary when criteria are met.

Absorbable nasal cartilage support implant (e.g., Latera) — definition and short-term evidence note

Absorbable nasal cartilage support implant — definitionA resorbable implant (e.g., Latera) placed to stabilize the lateral nasal wall/nasal valve to improve nasal airflow.

Evidence note (short-term)Current evidence shows short-term improvement in patient-reported outcomes up to 12 months in some cohorts, but overall evidence quality is low with limited long-term comparative data.

Clinical considerationsImplant procedures should be justified in the record; prior authorization is recommended given heterogeneous outcomes and limited long-term data.

Latera (bioabsorbable nasal implant) — definition

Latera — definitionA polylactic acid–based bioabsorbable nasal implant placed to support the lateral nasal wall for treatment of nasal valve collapse.

Key study evidenceProspective multicenter case series (Sidle et al.) and systematic reviews reported NOSE/QOL improvements up to 12 months; adverse events uncommon (~5%) and usually resolved.

LimitationsLack of long-term comparative trials versus rhinoplasty and heterogeneity of concomitant procedures limit strength of evidence.

Temperature-controlled radiofrequency (TCRF / VivAer) — definition

Temperature‑controlled radiofrequency (TCRF / VivAer) — definitionA minimally invasive device-based thermal treatment applied to septal swell body hypertrophy or nasal valve tissue to reduce tissue volume or produce remodeling and improve NAO symptoms.

ApplicationsUsed for septal swell body reduction (SSBVR) and for transmucosal neurolysis when applied over the PNN or for mechanical remodeling of the nasal valve.

Evidence summarySingle-arm and randomized trials report improvements in NOSE or symptom scores up to 24 months in selected cohorts, though some studies lack control arms and long-term data.

rTNSS / TNSS — definition

rTNSS / TNSS — definitionReflective Total Nasal Symptom Score (rTNSS) or Total Nasal Symptom Score (TNSS) are validated patient‑reported measures quantifying severity of nasal symptoms used as primary endpoints in many chronic rhinitis and neuroablative trials.

ComponentsScores include subscores for rhinorrhea, nasal congestion, sneezing, and itching; studies report 12‑ or 24‑hour rTNSS measures depending on protocol.

Use in trialsResponder definitions and enrollment thresholds often reference absolute rTNSS/TNSS values and subscore minimums.

ClariFix / RhinAer / TCRF — device definitions

ClariFix / RhinAer / TCRF — device definitionsClariFix delivers cryoablation to the posterior nasal nerve region; RhinAer delivers temperature‑controlled radiofrequency neurolysis to the PNN region; TCRF devices (e.g., VivAer) apply controlled radiofrequency energy for tissue remodeling or neurolysis.

IndicationsDevices are used for chronic rhinitis refractory to medical therapy (PNN ablation) or for SSB/valve remodeling depending on device and study population.

Evidence contextEvidence base includes RCTs and single‑arm studies with varying follow‑up durations; policy notes limitations and recommends alignment with trial eligibility for coverage decisions.

Responder — trial-specific definition

Responder — trial-specific definitionIn chronic rhinitis and nasal valve trials, responders are often defined as ≥30% reduction in rTNSS or ≥20% reduction in NOSE score, or at least one severity class improvement at specified follow‑up (e.g., 3 months).

Examples from pivotal trialsSilvers et al. (TCRF nasal valve) used ≥20% NOSE reduction or ≥1 severity class improvement; many PNN trials used ≥30% rTNSS reduction as responder definition.

Implication for outcomesResponder thresholds are used as primary endpoints in RCTs and inform expected clinical benefit and prior‑authorization criteria.

TCRF — definition (transmucosal temperature-controlled radiofrequency)

TCRF — definition (transmucosal)Transmucosal temperature‑controlled radiofrequency energy applied to the nasal mucosa overlying the posterior nasal nerve or nasal valve to produce neurolysis or tissue remodeling.

Delivery approachEnergy is delivered through a handheld stylus to targeted mucosal regions, with protocols specifying number and location of applications.

Therapeutic goalsAims to reduce symptom burden (rhinorrhea, congestion) via neurolysis for rhinitis or to remodel valve/SSB tissue to improve airflow.

External Nasal Valve — updated definition

External Nasal Valve — updated definition notePolicy indicates the External Nasal Valve definition has been updated in this version; updated text appears elsewhere in the policy but is noted in the revision history.

Reference anatomyOriginal definition includes lateral crus, soft tissue alae, membranous septum, and nostril sill as the entrance to the nose.

Operational noteProviders should refer to the policy text for the finalized updated External Nasal Valve definition when applying coverage criteria.